Neurocrine Biosciences | Pasivo Circulante



Current Liabilities Cambio Fecha
AbbVie USD 38.75B 4.31B 2024-12
Acadia Pharmaceuticals USD 302.53M 92.34M 2025-03
Agios Pharmaceuticals USD 52.37M 28.79M 2025-03
ALKERMES USD 443.73M 21.47M 2025-03
Alnylam Pharmaceuticals USD 1.08B 110.65M 2025-03
Amgen USD 23.01B 91M 2025-03
Biogen USD 5.3B 231.4M 2025-03
BioMarin Pharmaceutical USD 628.21M 21.22M 2025-03
Cytokinetics USD 159.73M 19.95M 2025-03
Dynavax Technologies USD 68.38M 10.26M 2025-03
Exelixis USD 399.1M 4.67M 2025-04
Gilead Sciences USD 12B 279M 2024-12
Halozyme Therapeutics USD 150.38M 11.28M 2025-03
Incyte USD 1.89B 244.96M 2025-03
Ionis Pharmaceuticals USD 250.29M 59.02M 2025-03
Neurocrine Biosciences USD 507.7M 78M 2024-12
Pfizer USD 36.45B 6.54B 2025-03
Prothena USD 48.5M 2.08M 2024-12
Regeneron Pharmaceuticals USD 3.57B 2.13B 2025-03
Repligen USD 152M 25.21M 2025-03
Sarepta Therapeutics USD 605.59M 126.1M 2025-03
Teva Pharmaceutical Industries USD 11.16B 1.64B 2025-03
Ultragenyx Pharmaceutical USD 344.15M 59.14M 2024-12
Vertex Pharmaceuticals USD 3.56B 408.5M 2024-12



Neurocrine Biosciences Pasivo Circulante - Los valores actuales, los datos históricos, las previsiones, estadísticas, gráficas y calendario económico - May 2025.